Acemox250 mg

Acemox is a carbonic anhydrase inhibitor used as adjunctive (add-on) therapy for several conditions, with the strength of evidence varying by indication:

FDA-approved / established uses

• Glaucoma: Adjunctive treatment of chronic open-angle glaucoma, secondary glaucoma, and short-term preoperative management of acute angle-closure glaucoma, by lowering intraocular pressure.
• Epilepsy: Adjunctive therapy (used together with other anticonvulsants) for centrencephalic epilepsies, including certain generalized (petit mal/absence) and mixed seizure patterns.
• Edema: Adjunctive treatment of edema due to congestive heart failure and drug-induced edema.
• Acute mountain sickness (altitude sickness): Prevention and reduction in severity of symptoms of acute mountain sickness in individuals undertaking rapid ascent to high altitude.

Commonly used off-label (not FDA-approved but supported by clinical practice/literature)

• Idiopathic intracranial hypertension (pseudotumor cerebri) to reduce cerebrospinal fluid production.
• Periodic paralysis syndromes (hypokalemic/hyperkalemic) in selected patients.
• Metabolic alkalosis in critically ill patients, as an adjunct.

Note: Acemox is always used as an adjunct in epilepsy and edema; it is not intended as sole/first-line therapy for these conditions.

Each tablet of Acetazolamide commonly contains 250 mg of acetazolamide as the active ingredient, along with standard pharmaceutical excipients such as binders, fillers, and disintegrants. Sustained-release capsule formulations (typically 500 mg) and a sterile injectable powder form also exist internationally, though tablets are the form most widely available in Bangladesh.

Acemox is a sulfonamide derivative that acts as a carbonic anhydrase inhibitor. Unlike antibacterial sulfonamides, it has no significant antibacterial activity but strongly inhibits the enzyme carbonic anhydrase in the eye, kidney, brain, and other tissues.

By inhibiting carbonic anhydrase, Acemox reduces the formation of aqueous humor in the eye (lowering intraocular pressure), promotes renal excretion of sodium, potassium, bicarbonate, and water (mild diuretic effect), and reduces excessive abnormal neuronal discharge in the central nervous system.

Carbonic anhydrase inhibitor; sulfonamide derivative (non-antibacterial); used as an anti-glaucoma agent, anticonvulsant adjunct, diuretic, and altitude-sickness prophylactic.

Acetazolamide is a potent, specific, non-competitive inhibitor of the enzyme carbonic anhydrase, which catalyzes the reversible reaction involving hydration of carbon dioxide and dehydration of carbonic acid.

• Ocular effect: Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases the secretion of aqueous humor, resulting in a drop in intraocular pressure.
• Renal effect: Inhibition of carbonic anhydrase in the renal proximal tubule reduces reabsorption of bicarbonate, sodium, and water, producing a mild diuretic and alkalinizing effect on urine, and can lead to metabolic acidosis with prolonged use.
• CNS effect: The anticonvulsant action is thought to relate to carbonic anhydrase inhibition in the brain, which may retard abnormal, paroxysmal, excessive discharge from neurons.
• Altitude sickness: Induced metabolic acidosis stimulates ventilation, improving oxygenation and reducing symptoms of acute mountain sickness.

Pharmacokinetics: Acetazolamide is well absorbed orally, is not metabolized, and is excreted unchanged by the kidneys, largely within 24 hours.

Acemox tablets are given by mouth, with or without food. Extended-release capsule forms (where available) are typically taken once or twice daily and should be swallowed whole, not chewed or crushed. Adequate fluid intake is recommended during therapy to reduce the risk of kidney stone formation.

The following are well-documented, clinically significant interactions with Acemox:

• High-dose aspirin (salicylates): Concomitant use can cause severe toxicity, including anorexia, tachypnea, lethargy, metabolic acidosis, coma, and death; avoid combination or use with extreme caution and close monitoring.
• Phenytoin: Acemox may increase serum phenytoin levels and increase the risk of osteomalacia with long-term combined use.
• Primidone: Acemox may decrease serum primidone concentrations.
• Other carbonic anhydrase inhibitors (e.g., topiramate, zonisamide, dorzolamide): Additive effects and increased risk of severe acid-base and electrolyte disturbances; concurrent use is generally not advisable.
• Lithium: Acemox increases renal excretion of lithium, which may reduce its therapeutic effect.
• Cyclosporine: May increase cyclosporine blood levels.
• Amphetamines, quinidine, methenamine: Alkalinization of urine by Acemox reduces urinary excretion of amphetamine and quinidine (enhancing their effect) and can prevent the antiseptic action of methenamine.
• Antidiabetic agents: Acemox can alter blood glucose control; monitor glucose closely in diabetic patients.
• Sodium bicarbonate: Concurrent use increases the risk of renal calculus (kidney stone) formation.

Side effects of Acemox range from common and generally mild to rare but serious:

Common

• Paresthesias (tingling/numbness), particularly of the fingers, toes, and around the mouth - usually mild and dose-related.
• Fatigue, drowsiness, malaise, headache.
• Loss of appetite, nausea, vomiting, altered taste, diarrhea.
• Increased urination (mild diuretic effect).

Less common / serious

• Metabolic acidosis and electrolyte disturbances (hypokalemia, hyponatremia) - see Contraindications/Precautions.
• Kidney stone (renal calculus) formation.
• Blood disorders: aplastic anemia, agranulocytosis, leukopenia, thrombocytopenia (rare but require monitoring with prolonged use).
• Liver dysfunction, including rare cholestatic jaundice or fulminant hepatic necrosis.
• Hypersensitivity/skin reactions: urticaria, photosensitivity, and rarely Stevens-Johnson syndrome or toxic epidermal necrolysis.
• Hearing disturbances, tinnitus.
• Transient myopia; rarely, choroidal effusion/detachment after ocular surgery.

Pregnancy: Acemox has shown teratogenic effects (limb defects) in animal reproduction studies. Acemox should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; consult a physician before use in pregnancy.

Lactation: It is not well established whether Acemox passes into breast milk in clinically significant amounts. Because of the potential for adverse effects in a nursing infant, a decision should be made, in consultation with a physician, whether to discontinue nursing or discontinue Acemox, taking into account the importance of the drug to the mother.

Sulfonamide hypersensitivity: Although Acemox is not an antibacterial sulfonamide, rare but fatal reactions similar to those seen with antibacterial sulfonamides (Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia) have occurred; discontinue immediately if signs of hypersensitivity appear.

Electrolyte and acid-base disturbances: Acemox can cause hyponatremia, hypokalemia, and metabolic acidosis, especially with prolonged use. Periodic monitoring of serum electrolytes is recommended.

Renal calculi: Adequate hydration is recommended during therapy to reduce the risk of kidney stone formation.

Blood dyscrasias: Baseline and periodic complete blood counts are recommended with prolonged therapy because of the (rare) risk of aplastic anemia and other blood disorders.

Hepatic/renal impairment: Use with caution and at reduced doses in mild-to-moderate impairment; contraindicated in severe impairment (see Contraindications).

CNS effects: May cause drowsiness, fatigue, or transient myopia; patients should be cautious when driving or operating machinery until they know how they respond to Acemox.

Pulmonary disease: Use with caution in patients with pulmonary obstruction or emphysema, where alveolar ventilation may be impaired.

Chronic angle-closure glaucoma: See Contraindications regarding long-term use.

Symptoms of Acemox overdose may include electrolyte imbalance, metabolic acidosis, drowsiness, and central nervous system disturbances. There is no specific antidote.

In case of suspected overdose, seek immediate medical attention or contact emergency services/a poison control center right away. Treatment is symptomatic and supportive, typically in a hospital setting, and may include monitoring and correction of serum electrolytes (particularly potassium) and blood pH. Acemox is removed by dialysis, which may be considered if overdose is complicated by renal failure. Do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use: The safety and effectiveness of Acemox in pediatric patients have not been formally established for all indications, though it is used clinically (e.g., for glaucoma and epilepsy) under medical supervision with weight-based dosing. Growth retardation has been reported with long-term use in children, thought to be related to chronic acidosis; growth should be monitored.

Geriatric use: Elderly patients, especially those with reduced renal function, are at greater risk of severe metabolic acidosis. Dosing should generally start at the lower end of the recommended range, with attention to renal, hepatic, and cardiac function.

Renal impairment: Use with caution in mild-to-moderate impairment (reduced effectiveness and increased risk of acidosis); contraindicated in severe renal disease.

Hepatic impairment: Use with caution; contraindicated in severe hepatic disease/cirrhosis due to risk of hepatic encephalopathy.

Duration of Acemox therapy depends on the indication and clinical response, and should be determined by the prescribing physician. For altitude sickness prevention, treatment is typically short-term (started 1-2 days before ascent, continued for 48 hours or more at altitude). For chronic conditions such as glaucoma or epilepsy, treatment may be long-term, with periodic monitoring of electrolytes, renal function, and blood counts. Long-term use for chronic non-congestive angle-closure glaucoma is not recommended (see Contraindications).

Carbonic anhydrase inhibitor (non-antibacterial sulfonamide derivative); antiglaucoma agent; anticonvulsant adjunct; diuretic.

Acetazolamide works by inhibiting the enzyme carbonic anhydrase, which normally catalyzes the conversion of carbon dioxide and water into carbonic acid (and its dissociation into bicarbonate and hydrogen ions). By blocking this enzyme in the eye, Acetazolamide reduces aqueous humor production and lowers intraocular pressure. In the kidney, inhibition of carbonic anhydrase reduces bicarbonate reabsorption, producing a mild diuretic and urine-alkalinizing effect and a tendency toward metabolic acidosis. In the central nervous system, this same mechanism is believed to raise the seizure threshold, and the resulting mild metabolic acidosis stimulates respiration, which is useful in preventing altitude sickness.

C

Acemox safety and efficacy have not been formally established in pediatric patients for most indications per product labeling; however, it is used in clinical practice (glaucoma, epilepsy, and pseudotumor cerebri) under close medical supervision, typically with weight-based (mg/kg) dosing. Long-term use in children has been associated with growth retardation (linked to chronic mild acidosis), so growth should be monitored during prolonged therapy. Use in children should only be under the direction of a pediatrician or pediatric specialist.